{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:10:34Z","timestamp":1740107434649,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T00:00:00Z","timestamp":1662681600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100013822","name":"Kurdistan University Of Medical Sciences","doi-asserted-by":"publisher","award":["IR.MUK.REC.1400.120"],"award-info":[{"award-number":["IR.MUK.REC.1400.120"]}],"id":[{"id":"10.13039\/501100013822","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1007\/s00280-022-04472-w","type":"journal-article","created":{"date-parts":[[2022,9,9]],"date-time":"2022-09-09T12:37:36Z","timestamp":1662727056000},"page":"389-397","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population"],"prefix":"10.1007","volume":"90","author":[{"given":"Mohammad","family":"Salmani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bayazid","family":"Ghaderi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Fotoohi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramtin","family":"Omid-Shafa\u2019at","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zakaria","family":"Vahabzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omid","family":"Fotouhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4766-0423","authenticated-orcid":false,"given":"Mohammad","family":"Abdi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,9]]},"reference":[{"key":"4472_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107447","volume":"206","author":"S Vodenkova","year":"2020","unstructured":"Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther 206:107447. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.107447","journal-title":"Pharmacol Ther"},{"issue":"3","key":"4472_CR2","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/cpt.2069","volume":"109","author":"JE Knikman","year":"2021","unstructured":"Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM (2021) Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 109(3):591\u2013604. https:\/\/doi.org\/10.1002\/cpt.2069","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"4472_CR3","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/bjc.2017.94","volume":"116","author":"D Meulendijks","year":"2017","unstructured":"Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers C, Soesan M, Cats A, Schellens JHM (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116(11):1415\u20131424. https:\/\/doi.org\/10.1038\/bjc.2017.94","journal-title":"Br J Cancer"},{"issue":"16","key":"4472_CR4","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/S1470-2045(15)00286-7","volume":"16","author":"D Meulendijks","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiader CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH (2015) Clinical relevance of DPYD as variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639\u20131650. https:\/\/doi.org\/10.1016\/S1470-2045(15)00286-7","journal-title":"Lancet Oncol"},{"key":"4472_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110416","author":"M Dolat","year":"2020","unstructured":"Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A (2020) Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph13110416","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"4472_CR6","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1111\/cts.12981","volume":"14","author":"TJ Wigle","year":"2021","unstructured":"Wigle TJ, Povitz BL, Medwid S, Teft WA, Legan RM, Lenehan J, Nevison S, Panuganty V, Keller D, Mailloux J, Siebring V, Sarma S, Choi YH, Welch S, Winquist E, Schwarz UI, Kim RB (2021) Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clin Transl Sci 14(4):1338\u20131348. https:\/\/doi.org\/10.1111\/cts.12981","journal-title":"Clin Transl Sci"},{"issue":"3","key":"4472_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s00280-016-3054-2","volume":"78","author":"JJ Lee","year":"2016","unstructured":"Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78(3):447\u2013464. https:\/\/doi.org\/10.1007\/s00280-016-3054-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"4472_CR8","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s12094-021-02708-4","volume":"24","author":"P Garcia-Alfonso","year":"2022","unstructured":"Garcia-Alfonso P, Saiz-Rodriguez M, Mondejar R, Salazar J, Paez D, Borobia AM, Safont MJ, Garcia-Garcia I, Colomer R, Garcia-Gonzalez X, Herrero MJ, Lopez-Fernandez LA, Abad-Santos F (2022) Consensus of experts from the Spanish pharmacogenetics and pharmacogenomics society and the Spanish society of medical oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol 24(3):483\u2013494. https:\/\/doi.org\/10.1007\/s12094-021-02708-4","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"4472_CR9","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1006\/geno.1998.5379","volume":"51","author":"X Wei","year":"1998","unstructured":"Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51(3):391\u2013400. https:\/\/doi.org\/10.1006\/geno.1998.5379","journal-title":"Genomics"},{"issue":"12","key":"4472_CR10","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1002\/onco.13967","volume":"26","author":"BB Sharma","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26(12):1008\u20131016. https:\/\/doi.org\/10.1002\/onco.13967","journal-title":"Oncologist"},{"issue":"12","key":"4472_CR11","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1093\/annonc\/mdx411","volume":"28","author":"LM Henricks","year":"2017","unstructured":"Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM (2017) DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol 28(12):2915\u20132922. https:\/\/doi.org\/10.1093\/annonc\/mdx411","journal-title":"Ann Oncol"},{"issue":"8","key":"4472_CR12","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41416-019-0423-8","volume":"120","author":"F Iachetta","year":"2019","unstructured":"Iachetta F, Bonelli C, Romagnani A, Zamponi R, Tofani L, Farnetti E, Nicoli D, Damato A, Banzi M, Casali B, Pinto C (2019) The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy an Italian case-control study. Br J Cancer 120(8):834\u2013839. https:\/\/doi.org\/10.1038\/s41416-019-0423-8","journal-title":"Br J Cancer"},{"issue":"2","key":"4472_CR13","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1002\/cpt.911","volume":"103","author":"U Amstutz","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210\u2013216. https:\/\/doi.org\/10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"4472_CR14","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2217\/pgs.15.70","volume":"16","author":"LM Henricks","year":"2015","unstructured":"Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, Schellens JH, Guchelaar HJ (2015) Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics 16(11):1277\u20131286. https:\/\/doi.org\/10.2217\/pgs.15.70","journal-title":"Pharmacogenomics"},{"issue":"9","key":"4472_CR15","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1002\/ijc.32022","volume":"144","author":"LM Henricks","year":"2019","unstructured":"Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM (2019) Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer 144(9):2347\u20132354. https:\/\/doi.org\/10.1002\/ijc.32022","journal-title":"Int J Cancer"},{"issue":"11","key":"4472_CR16","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/pgs.13.116","volume":"14","author":"S Terrazzino","year":"2013","unstructured":"Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA (2013) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14(11):1255\u20131272. https:\/\/doi.org\/10.2217\/pgs.13.116","journal-title":"Pharmacogenomics"},{"issue":"3","key":"4472_CR17","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.1016\/j.clcc.2019.04.005","volume":"18","author":"AS Maharjan","year":"2019","unstructured":"Maharjan AS, McMillin GA, Patel GK, Awan S, Taylor WR, Pai S, Frankel AE, Nelson C, Wang B, Hosein PJ, Singh AP, Khushman M (2019) The prevalence of DPYD*9A (c.85T>C) genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis. Clin Colorectal Cancer 18(3):e280\u2013e286. https:\/\/doi.org\/10.1016\/j.clcc.2019.04.005","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4472_CR18","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1186\/s12885-020-06904-3","volume":"20","author":"R Negarandeh","year":"2020","unstructured":"Negarandeh R, Salehifar E, Saghafi F, Jalali H, Janbabaei G, Abdhaghighi MJ, Nosrati A (2020) Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer 20(1):560. https:\/\/doi.org\/10.1186\/s12885-020-06904-3","journal-title":"BMC Cancer"},{"issue":"1","key":"4472_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.3289","volume":"23","author":"SM Naushad","year":"2021","unstructured":"Naushad SM, Hussain T, Alrokayan SA, Kutala VK (2021) Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med 23(1):e3289. https:\/\/doi.org\/10.1002\/jgm.3289","journal-title":"J Gene Med"},{"issue":"4","key":"4472_CR20","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1002\/cpt.685","volume":"102","author":"Q Nie","year":"2017","unstructured":"Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB (2017) Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 102(4):662\u2013670. https:\/\/doi.org\/10.1002\/cpt.685","journal-title":"Clin Pharmacol Ther"},{"unstructured":"National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm. Accessed 2 Feb 2021","key":"4472_CR21"},{"issue":"3","key":"4472_CR22","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3233\/CBM-160165","volume":"18","author":"R Heydarov","year":"2017","unstructured":"Heydarov R, Titov S, Abramov M, Timofeev E, Mikhailovich V (2017) Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes. Cancer Biomark 18(3):265\u2013272. https:\/\/doi.org\/10.3233\/CBM-160165","journal-title":"Cancer Biomark"},{"issue":"3","key":"4472_CR23","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1200\/JCO.2015.63.1325","volume":"34","author":"MJ Deenen","year":"2016","unstructured":"Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227\u2013234. https:\/\/doi.org\/10.1200\/JCO.2015.63.1325","journal-title":"J Clin Oncol"},{"issue":"4","key":"4472_CR24","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41431-019-0540-0","volume":"28","author":"C Lunenburg","year":"2020","unstructured":"Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ (2020) Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28(4):508\u2013517. https:\/\/doi.org\/10.1038\/s41431-019-0540-0","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"4472_CR25","first-page":"157","volume":"12","author":"MH Abbasian","year":"2020","unstructured":"Abbasian MH, Ansarinejad N, Abbasi B, Iravani M, Ramim T, Hamedi F, Ardekani AM (2020) The role of dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms in fluoropyrimidine-based cancer chemotherapy in an iranian population. Avicenna J Med Biotechnol 12(3):157\u2013164","journal-title":"Avicenna J Med Biotechnol"},{"issue":"9","key":"4472_CR26","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/bjc.2017.289","volume":"117","author":"A Ruzzo","year":"2017","unstructured":"Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M (2017) Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 117(9):1269\u20131277. https:\/\/doi.org\/10.1038\/bjc.2017.289","journal-title":"Br J Cancer"},{"issue":"1","key":"4472_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00280-017-3478-3","volume":"81","author":"NA Nahid","year":"2018","unstructured":"Nahid NA, Apu MNH, Islam MR, Shabnaz S, Chowdhury SM, Ahmed MU, Nahar Z, Islam MS, Islam MS, Hasnat A (2018) DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol 81(1):119\u2013129. https:\/\/doi.org\/10.1007\/s00280-017-3478-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"4472_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jpm8040045","author":"A Amirfallah","year":"2018","unstructured":"Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I, Basbinar Y (2018) DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med. https:\/\/doi.org\/10.3390\/jpm8040045","journal-title":"J Pers Med"},{"issue":"4","key":"4472_CR29","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1002\/onco.13626","volume":"26","author":"C Jolivet","year":"2021","unstructured":"Jolivet C, Nassabein R, Soulieres D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfe M, Vadnais C, Viens D, Aubin F (2021) Implementing DPYD*2A genotyping in clinical practice: the Quebec, Canada. Experience Oncologist 26(4):e597\u2013e602. https:\/\/doi.org\/10.1002\/onco.13626","journal-title":"Experience Oncologist"},{"issue":"6","key":"4472_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41397-019-0077-1","volume":"19","author":"M Del Re","year":"2019","unstructured":"Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R (2019) DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J 19(6):556\u2013563. https:\/\/doi.org\/10.1038\/s41397-019-0077-1","journal-title":"Pharmacogenomics J"},{"issue":"1","key":"4472_CR31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1016\/j.sjbs.2020.10.052","volume":"28","author":"MAM Aboul-Soud","year":"2021","unstructured":"Aboul-Soud MAM, Alzahrani AJ, Mahmoud A (2021) Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing. Saudi J Biol Sci 28(1):628\u2013634. https:\/\/doi.org\/10.1016\/j.sjbs.2020.10.052","journal-title":"Saudi J Biol Sci"},{"issue":"5","key":"4472_CR32","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00280-021-04236-y","volume":"87","author":"J Saarenheimo","year":"2021","unstructured":"Saarenheimo J, Wahid N, Eigeliene N, Ravi R, Salomons GS, Ojeda MF, Vijzelaar R, Jekunen A, van Kuilenburg ABP (2021) Preemptive screening of DPYD as part of clinical practice: high prevalence of a novel exon 4 deletion in the Finnish population. Cancer Chemother Pharmacol 87(5):657\u2013663. https:\/\/doi.org\/10.1007\/s00280-021-04236-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"4472_CR33","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.suronc.2020.09.016","volume":"35","author":"E Puerta-Garcia","year":"2020","unstructured":"Puerta-Garcia E, Urbano-Perez D, Carrasco-Campos MI, Perez-Ramirez C, Segura-Perez A, Calleja H, Canadas-Garre M (2020) Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma. Surg Oncol 35:388\u2013398. https:\/\/doi.org\/10.1016\/j.suronc.2020.09.016","journal-title":"Surg Oncol"},{"issue":"3","key":"4472_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1002\/cpt.531","volume":"101","author":"T Elraiyah","year":"2017","unstructured":"Elraiyah T, Jerde CR, Shrestha S, Wu R, Nie Q, Giama NH, Sarangi V, Roberts LR, Offer SM, Diasio RB (2017) Novel deleterious dihydropyrimidine dehydrogenase variants may contribute to 5-fluorouracil sensitivity in an East African population. Clin Pharmacol Ther 101(3):382\u2013390. https:\/\/doi.org\/10.1002\/cpt.531","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"4472_CR35","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.3346\/jkms.2013.28.8.1129","volume":"28","author":"JG Shin","year":"2013","unstructured":"Shin JG, Cheong HS, Kim JY, Kim LH, Han CS, Kim JO, Kim HD, Kim YH, Chung MW, Han SY, Shin HD (2013) Screening of dihydropyrimidine dehydrogenase genetic variants by direct sequencing in different ethnic groups. J Korean Med Sci 28(8):1129\u20131133. https:\/\/doi.org\/10.3346\/jkms.2013.28.8.1129","journal-title":"J Korean Med Sci"},{"issue":"5","key":"4472_CR36","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1038\/s41416-020-0962-z","volume":"123","author":"N Pallet","year":"2020","unstructured":"Pallet N, Hamdane S, Garinet S, Blons H, Zaanan A, Paillaud E, Taieb J, Laprevote O, Loriot MA, Narjoz C (2020) A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency. Br J Cancer 123(5):811\u2013818. https:\/\/doi.org\/10.1038\/s41416-020-0962-z","journal-title":"Br J Cancer"},{"issue":"1","key":"4472_CR37","doi-asserted-by":"publisher","first-page":"68","DOI":"10.20524\/aog.2020.0551","volume":"34","author":"S Detailleur","year":"2021","unstructured":"Detailleur S, Segelov E, Re MD, Prenen H (2021) Dihydropyrimidine dehydrogenase deficiency in patients with severe toxicity after 5-fluorouracil: a retrospective single-center study. Ann Gastroenterol 34(1):68\u201372. https:\/\/doi.org\/10.20524\/aog.2020.0551","journal-title":"Ann Gastroenterol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04472-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04472-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T18:03:08Z","timestamp":1665597788000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04472-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,9]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4472"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04472-w","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2022,9,9]]},"assertion":[{"value":"3 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M Salmani declares no potential conflicts of interest with respect to the research, authorship, and\/or publication of this article. B Ghaderi declares that he has no conflict of interest. A Fotoohi declares that he has no conflict of interest. R Omid-Shafa'at declares that he has no conflict of interest. Z Vahabzadeh declares that he has no conflict of interest. O Fotouhi declares that he has no conflict of interest. M Abdi has received research grants from the Kurdistan University of medical sciences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"conflict of interest"}},{"value":"All procedures performed in studies involving human participants followed the ethical standards of the ethics committee of Kurdistan University of Medical Sciences and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}